Because IL-6 and other cytokines are critically involved in the pathogenesis of ACD, biologic therapies such as TCZ and TNF inhibitors could potentially increase hemoglobin (Hb) levels after treatment. Here, IL6 is linked to granular corneal dystrophy type II.